Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Genotypic resistance testing is now a standard of care in HIV management. Although there are clear, published guidelines to recommend the appropriate use of these tests, clinicians and scientists still struggle to determine the optimal use of resistance tests given the finite budgets and time constraints under which they work. In this article we discuss some 'real-life' clinical situations and aim to provide a useful insight into when and where genotypic resistance testing can be optimally applied in the management of HIV-positive adults.

Original publication




Journal article


The Journal of antimicrobial chemotherapy

Publication Date





218 - 222


Directorate of Sexual Medicine and HIV, Birmingham Heartlands Hospital, Heart of England NHS Foundation Trust, Birmingham, UK.


Humans, HIV, HIV Infections, Anti-HIV Agents, Microbial Sensitivity Tests, Genotype, Adult, Female, Male, Guidelines as Topic